Trial Profile
An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain; Musculoskeletal pain
- Focus Adverse reactions; Therapeutic Use
- 14 Oct 2023 Planned initiation date changed from 1 Oct 2023 to 1 Oct 2024.
- 17 Aug 2023 Planned initiation date changed from 1 Aug 2023 to 1 Oct 2023.
- 14 Jun 2023 Planned initiation date changed from 1 Jun 2023 to 1 Aug 2023.